Advanced Cancer Clinical Trial
Official title:
The Experience of Fatigue for Patients With Cancer
The goal of this research study is to learn what it is like when a patient with cancer has fatigue, as well as how these patients define fatigue. Researchers want to use this information to create questionnaires that may more accurately measure fatigue and its effects in patients with cancer.
STUDY PARTICIPATION:
If you agree to take part in this study, you will be interviewed by a member of the study
staff and then asked to complete a series of questionnaires and verbal (spoken) questions.
During the interview, you will be asked to describe what fatigue means to you and what it is
like for you to have fatigue. The interview will take place while you are at M. D. Anderson
receiving your routine care. You will be interviewed alone, and the information gathered
during the interview will be kept strictly confidential. The interview will take about 30
minutes to complete. It will be audiotaped so that participants' responses can be fully
analyzed.
You will then be asked to complete 4 questionnaires and answer 2 separate questions.
The first questionnaire will include questions about your personal identifying information
(such as your age and marital status).
You will then be asked 1 question about your quality of life and another question about how
well you are performing day-to-day activities.
You will then be asked to complete a second questionnaire in which you will rate your
fatigue level and how fatigue interferes with your daily activities.
You will be asked to complete a third questionnaire about your opinion of the fatigue
questionnaire (the second questionnaire). For example, you will be asked if the fatigue
questionnaire was easy to understand and to complete. Learning your opinion about this
questionnaire will help researchers learn what important questions may be missing from the
questionnaire.
Finally, you will then be asked to complete a questionnaire that asks you to rate the
severity of a list of 13 symptoms and how much these symptoms interfere with some of your
daily activities.
The questionnaires and additional questions should take a total of 15-20 minutes to
complete.
After you have completed the interview and questionnaires, a research assistant will review
your electronic medical record to collect information about your disease and treatments.
LENGTH OF STUDY:
Your participation in this study will be over after you complete the interview, the
questionnaires, and the additional questions.
This is an investigational study. Up to 60 patients will take part in this study. All will
be enrolled at M. D. Anderson.
;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
| Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
| Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
| Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
| Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
| Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
| Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
| Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT01901237 -
Yoga for Adolescent and Young Adult Non-Curative Cancer Patients
|
N/A |